A Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe in Asia in High Cardiovascular Risk Patients With Hypercholesterolemia Not Adequately Controlled With Their Statin Therapy

Trial Profile

A Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe in Asia in High Cardiovascular Risk Patients With Hypercholesterolemia Not Adequately Controlled With Their Statin Therapy

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 04 Apr 2018

At a glance

  • Drugs Alirocumab (Primary) ; Ezetimibe
  • Indications Hypercholesterolaemia
  • Focus Therapeutic Use
  • Acronyms ODYSSEY EAST
  • Sponsors Sanofi
  • Most Recent Events

    • 27 Mar 2018 Status changed from recruiting to active, no longer recruiting.
    • 14 Feb 2018 Planned End Date changed from 1 Jun 2018 to 10 Aug 2018.
    • 14 Feb 2018 Planned primary completion date changed from 1 Jun 2018 to 10 Aug 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top